Skip to main content
Erschienen in: Tumor Biology 7/2014

01.07.2014 | Research Article

7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells

verfasst von: Dermot O’Sullivan, Michael Henry, Helena Joyce, Naomi Walsh, Edel Mc Auley, Paul Dowling, Niall Swan, Michael Moriarty, Paul Barnham, Martin Clynes, Annemarie Larkin

Erschienen in: Tumor Biology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Development of more effective therapeutic strategies for cancers of high unmet need requires the continued discovery of disease-specific protein targets for therapeutic antibody targeting. In order to identify novel proteins associated with cancer cell invasion/metastasis, we present here an alternative to antibody targeting of cell surface proteins with an established role in invasion; our functional antibody screening approach involves the isolation and selection of MAbs that are primarily screened for their ability to inhibit tumour invasion. A clonal population of the Mia PaCa-2, a pancreatic ductal adenocarcinoma (PDAC) cell line, which displays a highly invasive phenotype, was used to generate MAbs with the objective of identifying membrane targets directly involved in cancer invasion. Selected MAb 7B7 can significantly reduce invasion in a dose-responsive manner in Mia PaCa-2 clone 3 and DLKP-M squamous lung carcinoma cells. Using immunoprecipitation and liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis, the target antigen of anti-invasive antibody, 7B7, was determined to be the heterodimeric Ku antigen, Ku70/80, a core protein composed of the Ku70 and Ku80 subunits which is involved in non-homologous end-joining (NHEJ) DNA repair. RNA interference-mediated knockdown of Ku70 and Ku80 resulted in a marked decrease in the invasive capacity of Mia PaCa-2 clone 3 and DLKP-M cells, indicating that Ku70/Ku80 is functionally involved in pancreatic and lung cancer invasion. Immunohistochemical analysis demonstrated Ku70/Ku80 immunoreactivity in 37 PDAC tumours, indicating that this heterodimer is highly expressed in this aggressive cancer type. This study demonstrates that a functional MAb screening approach coupled with immunoprecipitation/proteomic analyses can be successfully applied to identify functional anti-invasive MAbs and potential novel targets for therapeutic antibody targeting.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Disc. 2012;11:479–97.CrossRef Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Disc. 2012;11:479–97.CrossRef
2.
Zurück zum Zitat Weber GF. Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett. 2013;328:207–11.CrossRefPubMed Weber GF. Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett. 2013;328:207–11.CrossRefPubMed
4.
Zurück zum Zitat Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220–33.PubMedCentralCrossRefPubMed Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220–33.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.CrossRefPubMed Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.CrossRefPubMed
8.
9.
Zurück zum Zitat Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12(5):329–32.CrossRefPubMed Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12(5):329–32.CrossRefPubMed
10.
Zurück zum Zitat Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29.CrossRefPubMed Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29.CrossRefPubMed
12.
Zurück zum Zitat Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507–19.CrossRefPubMed Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507–19.CrossRefPubMed
13.
Zurück zum Zitat Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.CrossRefPubMed Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.CrossRefPubMed
14.
Zurück zum Zitat Kinch MS, Kohli M, Goldblatt M, Li WB. Function-first approaches to improve target identification in cancer. Future Oncol. 2009;5(5):617–23.CrossRefPubMed Kinch MS, Kohli M, Goldblatt M, Li WB. Function-first approaches to improve target identification in cancer. Future Oncol. 2009;5(5):617–23.CrossRefPubMed
15.
Zurück zum Zitat Frendeus B. Function-first antibody discovery: embracing the unpredictable biology of antibodies. Oncoimmunol. 2013;2(8):e25047.CrossRef Frendeus B. Function-first antibody discovery: embracing the unpredictable biology of antibodies. Oncoimmunol. 2013;2(8):e25047.CrossRef
16.
Zurück zum Zitat Rust S, Guillard S, Sachsenmeier K, Hay C, Davidson M, Karlsson A, et al. Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type. Mol Cancer. 2013;12:11.PubMedCentralCrossRefPubMed Rust S, Guillard S, Sachsenmeier K, Hay C, Davidson M, Karlsson A, et al. Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type. Mol Cancer. 2013;12:11.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Walsh N, Dowling P, O'Donovan N, Henry M, Meleady P, Clynes M. Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells. J Proteomics. 2008;71(5):561–71.CrossRefPubMed Walsh N, Dowling P, O'Donovan N, Henry M, Meleady P, Clynes M. Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells. J Proteomics. 2008;71(5):561–71.CrossRefPubMed
18.
Zurück zum Zitat McBride S, Meleady P, Baird A, Dinsdale D, Clynes M. Human lung carcinoma cell line DLKP contains 3 distinct subpopulations with different growth and attachment properties. Tumour Biol. 1998;19(2):88–103.CrossRefPubMed McBride S, Meleady P, Baird A, Dinsdale D, Clynes M. Human lung carcinoma cell line DLKP contains 3 distinct subpopulations with different growth and attachment properties. Tumour Biol. 1998;19(2):88–103.CrossRefPubMed
19.
Zurück zum Zitat Walsh N, Clynes M, Crown J, O'Donovan N. Alterations in integrin expression modulates invasion of pancreatic cancer cells. J Exp Clin Cancer Res. 2009;28:140.PubMedCentralCrossRefPubMed Walsh N, Clynes M, Crown J, O'Donovan N. Alterations in integrin expression modulates invasion of pancreatic cancer cells. J Exp Clin Cancer Res. 2009;28:140.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res. 1998;4(3):230–41.CrossRefPubMed Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res. 1998;4(3):230–41.CrossRefPubMed
21.
Zurück zum Zitat Martin A, Clynes M. Acid phosphatase: endpoint for in vitro toxicity tests. In Vitro Cell Dev Biol. 1991;27A(3 Pt 1):183–4.CrossRefPubMed Martin A, Clynes M. Acid phosphatase: endpoint for in vitro toxicity tests. In Vitro Cell Dev Biol. 1991;27A(3 Pt 1):183–4.CrossRefPubMed
22.
Zurück zum Zitat Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 2006;1(6):2856–60.CrossRefPubMed Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 2006;1(6):2856–60.CrossRefPubMed
23.
Zurück zum Zitat Larkin A, Moran E, Kennedy SM, Clynes M. Monoclonal antibody 5C3 raised against formalin fixed paraffin-embedded invasive breast tumour tissue: characterisation of its reactive antigen via immunoprecipitation and internal sequencing. J Immunol Methods. 2005;303(1–2):53–65.CrossRefPubMed Larkin A, Moran E, Kennedy SM, Clynes M. Monoclonal antibody 5C3 raised against formalin fixed paraffin-embedded invasive breast tumour tissue: characterisation of its reactive antigen via immunoprecipitation and internal sequencing. J Immunol Methods. 2005;303(1–2):53–65.CrossRefPubMed
24.
Zurück zum Zitat Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–52.CrossRefPubMed Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–52.CrossRefPubMed
25.
Zurück zum Zitat Tuteja N, Tuteja R, Ochem A, Taneja P, Huang NW, Simoncsits A, et al. Human DNA helicase II: a novel DNA unwinding enzyme identified as the Ku autoantigen. EMBO J. 1994;13(20):4991–5001.PubMedCentralPubMed Tuteja N, Tuteja R, Ochem A, Taneja P, Huang NW, Simoncsits A, et al. Human DNA helicase II: a novel DNA unwinding enzyme identified as the Ku autoantigen. EMBO J. 1994;13(20):4991–5001.PubMedCentralPubMed
26.
Zurück zum Zitat Muller C, Paupert J, Monferran S, Salles B. The double life of the Ku protein: facing the DNA breaks and the extracellular environment. Cell Cycle. 2005;4(3):438–41.CrossRefPubMed Muller C, Paupert J, Monferran S, Salles B. The double life of the Ku protein: facing the DNA breaks and the extracellular environment. Cell Cycle. 2005;4(3):438–41.CrossRefPubMed
27.
Zurück zum Zitat Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene. 2007;26(17):2423–34.CrossRefPubMed Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene. 2007;26(17):2423–34.CrossRefPubMed
28.
Zurück zum Zitat Jia Q, Li Y, Xu D, Li Z, Zhang Z, Zhang Y, et al. Radiosensitivity of glioma to Gamma Knife treatment enhanced in vitro and in vivo by RNA interfering Ku70 that is mediated by a recombinant adenovirus. J Neurosurg. 2010;113(Suppl):228–35.PubMed Jia Q, Li Y, Xu D, Li Z, Zhang Z, Zhang Y, et al. Radiosensitivity of glioma to Gamma Knife treatment enhanced in vitro and in vivo by RNA interfering Ku70 that is mediated by a recombinant adenovirus. J Neurosurg. 2010;113(Suppl):228–35.PubMed
29.
Zurück zum Zitat SoderlundLeifler K, Queseth S, Fornander T, Askmalm MS. Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol. 2010;37(6):1547–54. SoderlundLeifler K, Queseth S, Fornander T, Askmalm MS. Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol. 2010;37(6):1547–54.
30.
Zurück zum Zitat Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumour Biol. 2011;32(5):1031–47.CrossRefPubMed Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumour Biol. 2011;32(5):1031–47.CrossRefPubMed
31.
Zurück zum Zitat Petera J, Sirak I, Beranek M, Vosmik M, Drastikova M, Paulikova S, et al. Molecular predictive factors of outcome of radiotherapy in cervical cancer. Neoplasma. 2011;58(6):469–75.CrossRefPubMed Petera J, Sirak I, Beranek M, Vosmik M, Drastikova M, Paulikova S, et al. Molecular predictive factors of outcome of radiotherapy in cervical cancer. Neoplasma. 2011;58(6):469–75.CrossRefPubMed
32.
Zurück zum Zitat Bouchaert P, Guerif S, Debiais C, Irani J, Fromont G. DNA-PKcs expression predicts response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1179–85.CrossRefPubMed Bouchaert P, Guerif S, Debiais C, Irani J, Fromont G. DNA-PKcs expression predicts response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1179–85.CrossRefPubMed
33.
Zurück zum Zitat Groselj B, Kerr M, Kiltie AE. Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. Radiother Oncol. 2013;108(3):429–33.PubMedCentralCrossRefPubMed Groselj B, Kerr M, Kiltie AE. Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. Radiother Oncol. 2013;108(3):429–33.PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Ma Q, Li P, Xu M, Yin J, Su Z, Li W, et al. Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance. J Exp Clin Cancer Res. 2012;31:99.PubMedCentralCrossRefPubMed Ma Q, Li P, Xu M, Yin J, Su Z, Li W, et al. Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance. J Exp Clin Cancer Res. 2012;31:99.PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Monferran S, Paupert J, Dauvillier S, Salles B, Muller C. The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J. 2004;23(19):3758–68.PubMedCentralCrossRefPubMed Monferran S, Paupert J, Dauvillier S, Salles B, Muller C. The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J. 2004;23(19):3758–68.PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Persson O, Salford LG, Fransson J, Widegren B, Borrebaeck CA, Holmqvist B. Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme. J Neuro Oncol. 2010;97(2):207–15.CrossRef Persson O, Salford LG, Fransson J, Widegren B, Borrebaeck CA, Holmqvist B. Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme. J Neuro Oncol. 2010;97(2):207–15.CrossRef
37.
Zurück zum Zitat Fransson J, Borrebaeck CA. The nuclear DNA repair protein Ku70/80 is a tumor-associated antigen displaying rapid receptor mediated endocytosis. Int J Cancer. 2006;119(10):2492–6.CrossRefPubMed Fransson J, Borrebaeck CA. The nuclear DNA repair protein Ku70/80 is a tumor-associated antigen displaying rapid receptor mediated endocytosis. Int J Cancer. 2006;119(10):2492–6.CrossRefPubMed
38.
Zurück zum Zitat Lagadec C, Romon R, Tastet C, Meignan S, Com E, Page A, et al. Ku86 is important for TrkA overexpression-induced breast cancer cell invasion. Proteomics Clin Appl. 2010;4(6–7):580–90.CrossRefPubMed Lagadec C, Romon R, Tastet C, Meignan S, Com E, Page A, et al. Ku86 is important for TrkA overexpression-induced breast cancer cell invasion. Proteomics Clin Appl. 2010;4(6–7):580–90.CrossRefPubMed
39.
Zurück zum Zitat Alshareeda AT, Negm OH, Albarakati N, Green AR, Nolan C, Sultana R, et al. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast Cancer Res Treat. 2013;139(2):301–10.CrossRefPubMed Alshareeda AT, Negm OH, Albarakati N, Green AR, Nolan C, Sultana R, et al. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast Cancer Res Treat. 2013;139(2):301–10.CrossRefPubMed
40.
Zurück zum Zitat Li W, Xie C, Yang Z, Chen J, Lu NH. Abnormal DNA-PKcs and Ku 70/80 expression may promote malignant pathological processes in gastric carcinoma. World J Gastroenterol. 2013;19(40):6894–901.PubMedCentralCrossRefPubMed Li W, Xie C, Yang Z, Chen J, Lu NH. Abnormal DNA-PKcs and Ku 70/80 expression may promote malignant pathological processes in gastric carcinoma. World J Gastroenterol. 2013;19(40):6894–901.PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Ferenczi K, Ohtola J, Aubert P, Kessler M, Sugiyama H, Somani AK, et al. Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70. Br J Dermatol. 2010;163(3):564–71.PubMedCentralCrossRefPubMed Ferenczi K, Ohtola J, Aubert P, Kessler M, Sugiyama H, Somani AK, et al. Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70. Br J Dermatol. 2010;163(3):564–71.PubMedCentralCrossRefPubMed
42.
Zurück zum Zitat Pucci S, Mazzarelli P, Sesti F, Boothman DA, Spagnoli LG. Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression. Cell Cycle. 2009;8(3):473–81.PubMedCentralCrossRefPubMed Pucci S, Mazzarelli P, Sesti F, Boothman DA, Spagnoli LG. Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression. Cell Cycle. 2009;8(3):473–81.PubMedCentralCrossRefPubMed
43.
Zurück zum Zitat Korabiowska M, Tscherny M, Stachura J, Berger H, Cordon-Cardo C, Brinck U. Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. Mod Pathol. 2002;15(4):426–33.CrossRefPubMed Korabiowska M, Tscherny M, Stachura J, Berger H, Cordon-Cardo C, Brinck U. Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. Mod Pathol. 2002;15(4):426–33.CrossRefPubMed
44.
Zurück zum Zitat Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, et al. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010;10(3):319–31.PubMedCentralCrossRefPubMed Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, et al. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010;10(3):319–31.PubMedCentralCrossRefPubMed
Metadaten
Titel
7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells
verfasst von
Dermot O’Sullivan
Michael Henry
Helena Joyce
Naomi Walsh
Edel Mc Auley
Paul Dowling
Niall Swan
Michael Moriarty
Paul Barnham
Martin Clynes
Annemarie Larkin
Publikationsdatum
01.07.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1857-5

Weitere Artikel der Ausgabe 7/2014

Tumor Biology 7/2014 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.